SPRO
Spero Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-23/100
Last price
1.19
▲ 0.03 (2.59%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
1.16
Day high
1.21
Day low
1.18
Volume
347.57K
Market cap
$69.30M
P/E (TTM)
8.50
52W range
1.08 – 3.08
Trailing performance
Returnvs SPY
1W
-0.83%
-2.8%
1M
-1.65%
-2.8%
3M
-45.16%
-49.7%
6M
-55.43%
-73.6%
YTD
-48.93%
-63.2%
1Y
-41.95%
-58.4%
3Y
-1.65%
-83.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SPRO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+207.07K
Net buying
Buy transactions
8
232.31K shares
Sell transactions
1
25.24K shares
Net transactions
+9
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
13.20M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 3, 26 | ZACK DEBRA JESKE Officer |
STOCK | 162.31K | $0 | Direct |
| Jun 23, 26 | SMITH CYNTHIA Director |
STOCK | 10.00K | $0 | Direct |
| Jun 23, 26 | THOMAS FRANK E Director |
STOCK | 10.00K | $0 | Direct |
| Jun 23, 26 | DESHPANDE MILIND S Director |
STOCK | 10.00K | $0 | Direct |
| Jun 23, 26 | POTTAGE JOHN C JR Director |
STOCK | 10.00K | $0 | Direct |
| Jun 23, 26 | VINK PATRICK V.J.J M.D. Director |
STOCK | 10.00K | $0 | Direct |
| Jun 23, 26 | JACKSON SCOTT THOMAS Director |
STOCK | 10.00K | $0 | Direct |
| Jun 23, 26 | TREGONING KATHLEEN Director |
STOCK | 10.00K | $0 | Direct |
| May 4, 26 | RAJAVELU ESTHER Chief Executive Officer |
SELL | 25.24K | $63.35K | Direct |
| Feb 6, 26 | KEUTZER TIMOTHY Chief Operating Officer |
SELL | 18.65K | $44.02K | Direct |
| Feb 6, 26 | RAJAVELU ESTHER Chief Executive Officer |
SELL | 87.92K | $207.48K | Direct |
| Feb 4, 26 | KEUTZER TIMOTHY Chief Operating Officer |
SELL | 46.59K | $101.17K | Direct |
| Feb 2, 26 | RAJAVELU ESTHER Chief Executive Officer |
SELL | 18.44K | $40.57K | Direct |
| Feb 2, 26 | KEUTZER TIMOTHY Chief Operating Officer |
STOCK | 68.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
DESHPANDE MILIND S |
Director | 101.45K | Stock Award(Grant) |
JACKSON SCOTT THOMAS |
Director | 85.00K | Stock Award(Grant) |
KEUTZER TIMOTHY |
Chief Operating Officer | 742.51K | Sale |
MAHADEVIA ANKIT |
Director | 703.29K | Sale |
POTTAGE JOHN C JR |
Director | 85.00K | Stock Award(Grant) |
RAJAVELU ESTHER |
Chief Executive Officer | 986.85K | Sale |
SHUKLA SATH |
Chief Executive Officer | 1.74M | Sale |
SMITH CYNTHIA |
Director | 85.00K | Stock Award(Grant) |
VINK PATRICK V.J.J M.D. |
Director | 85.00K | Stock Award(Grant) |
ZACK DEBRA JESKE |
Officer | 162.31K | Stock Award(Grant) |
Fundamentals
Market cap$69.30M
Enterprise value$20.57M
Revenue (TTM)$47.00M
Gross profit$26.46M
EBITDA—
Net income$7.38M
EPS (TTM)$0.14
Free cash flow$28.85M
Total cash$50.77M
Total debt$2.04M
Book value / share$0.76
Shares outstanding58.23M
Float47.10M
Short % of float2.02%
Dividend yield0.00%
Beta (5Y)1.50
Valuation & profitability ratios
Trailing P/E8.50
Forward P/E-1.07
PEG ratio—
Price / sales—
Price / book1.57
EV / revenue0.44
EV / EBITDA—
Gross margin56.31%
Operating margin14.07%
Profit margin15.71%
Return on equity19.17%
Return on assets7.19%
Debt / equity4.62
Current ratio6.12
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $59.62M | $27.40M | $96.73M | $48.58M | +117.6% |
| Operating revenue | $59.62M | $27.40M | $96.73M | $48.58M | +117.6% |
| Research & development | $38.47M | $96.76M | $51.44M | $47.59M | -60.2% |
| Selling, general & admin | $21.18M | $23.70M | $25.55M | $36.48M | -10.7% |
| Total operating expense | $52.46M | $99.88M | $69.95M | $79.15M | -47.5% |
| Operating income | $7.16M | -$72.48M | $26.79M | -$30.57M | +109.9% |
| Net interest income | $2.51M | $4.74M | $3.94M | -$1.50M | -46.9% |
| Pre-tax income | $8.83M | -$68.57M | $25.40M | -$46.41M | +112.9% |
| Tax provision | $261.00K | $0 | $2.60M | $0 | — |
| Net income | $8.57M | -$68.57M | $22.81M | -$46.41M | +112.5% |
| Net income to common | $8.57M | -$68.57M | $22.81M | -$46.41M | +112.5% |
| Basic EPS | 0.15 | -1.27 | 0.43 | -1.23 | +111.8% |
| Diluted EPS | 0.15 | -1.27 | 0.43 | -1.23 | +111.8% |
| EBIT | $7.16M | -$72.48M | $26.79M | -$43.81M | +109.9% |
| EBITDA | $7.16M | -$72.48M | $27.15M | -$42.94M | +109.9% |
| Basic shares | 56.02M | 54.04M | 52.70M | 37.59M | +3.7% |
| Diluted shares | 59.04M | 54.04M | 52.99M | 37.59M | +9.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $40.27M | $52.89M | $76.33M | $109.11M | -23.9% |
| Cash & short-term investments | $40.27M | $52.89M | $76.33M | $109.11M | -23.9% |
| Total current assets | $67.29M | $107.28M | $131.21M | $113.57M | -37.3% |
| Property, plant & equipment | $1.48M | $3.11M | $4.16M | $5.49M | -52.5% |
| Total assets | $68.92M | $110.54M | $182.39M | $124.80M | -37.7% |
| Total current liabilities | $8.87M | $49.07M | $37.15M | $21.65M | -81.9% |
| Total debt | $2.90M | $4.30M | $5.54M | $6.65M | -32.6% |
| Total liabilities | $9.90M | $64.42M | $75.50M | $48.87M | -84.6% |
| Retained earnings | -$451.07M | -$459.64M | -$391.07M | -$413.88M | +1.9% |
| Shareholder equity | $59.02M | $46.12M | $106.89M | $75.93M | +28.0% |
| Working capital | $58.42M | $58.20M | $94.06M | $91.92M | +0.4% |
| Net tangible assets | $59.02M | $46.12M | $106.89M | $75.93M | +28.0% |
| Shares issued | 56.41M | 54.59M | 53.00M | 52.46M | +3.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $8.57M | -$68.57M | $22.81M | -$46.41M | — | +112.5% |
| Depreciation & amortisation | $0 | $2.00K | $367.00K | $869.00K | — | -100.0% |
| Stock-based compensation | $4.33M | $7.79M | $7.93M | $9.12M | — | -44.5% |
| Change in working capital | -$27.16M | $36.28M | -$70.38M | $22.09M | — | -174.8% |
| Operating cash flow | -$12.62M | -$23.44M | -$32.99M | -$7.73M | — | +46.2% |
| Investing cash flow | — | — | $0 | $33.81M | $7.67M | — |
| Financing cash flow | — | $0 | $221.00K | -$29.55M | $84.05M | — |
| Free cash flow | -$12.62M | -$23.44M | -$32.99M | -$7.73M | — | +46.2% |
| End cash position | $40.27M | $52.89M | $76.33M | $109.11M | — | -23.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $258.00K | $39.66M | $3.05M | $11.80M | -100.0% |
| Operating revenue | $0 | $258.00K | $39.66M | $3.05M | $11.80M | -100.0% |
| Research & development | $3.43M | $2.91M | $5.59M | $8.60M | $10.67M | +18.0% |
| Selling, general & admin | $6.49M | $4.89M | $4.30M | $4.17M | $5.88M | +32.8% |
| Total operating expense | $9.93M | $7.80M | $8.25M | $10.38M | $14.16M | +27.3% |
| Operating income | -$9.93M | -$7.54M | $31.41M | -$7.33M | -$2.36M | -31.7% |
| Net interest income | $377.00K | $336.00K | $376.00K | $532.00K | $740.00K | +12.2% |
| Pre-tax income | -$9.55M | -$7.20M | $31.78M | -$7.38M | -$1.70M | -32.6% |
| Tax provision | — | — | $261.00K | $0 | — | — |
| Net income | -$9.55M | -$7.20M | $31.52M | -$7.38M | -$1.70M | -32.6% |
| Net income to common | -$9.55M | -$7.20M | $31.52M | -$7.38M | -$1.70M | -32.6% |
| Basic EPS | -0.16 | -0.13 | 0.56 | -0.13 | -0.03 | -23.1% |
| Diluted EPS | -0.16 | -0.13 | 0.53 | -0.13 | -0.03 | -23.1% |
| EBIT | -$9.93M | -$7.54M | $31.41M | -$7.33M | -$2.36M | -31.7% |
| EBITDA | -$9.93M | -$7.54M | $31.41M | -$7.33M | -$2.36M | -31.7% |
| Basic shares | 57.97M | 57.28M | 56.02M | 56.28M | 56.03M | +1.2% |
| Diluted shares | 57.97M | 57.28M | 59.37M | 56.28M | 56.03M | +1.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $50.77M | $56.13M | $40.27M | $48.62M | $31.19M | -9.5% |
| Cash & short-term investments | $50.77M | $56.13M | $40.27M | $48.62M | $31.19M | -9.5% |
| Total current assets | $51.58M | $57.61M | $67.29M | $52.32M | $59.40M | -10.5% |
| Property, plant & equipment | $1.03M | $1.26M | $1.48M | $1.69M | $2.56M | -18.1% |
| Total assets | $52.77M | $59.02M | $68.92M | $54.17M | $62.12M | -10.6% |
| Total current liabilities | $8.43M | $5.49M | $8.87M | $13.65M | $14.95M | +53.5% |
| Total debt | $2.04M | $2.47M | $2.90M | $3.35M | $3.62M | -17.4% |
| Total liabilities | $8.56M | $6.09M | $9.90M | $27.68M | $29.29M | +40.7% |
| Retained earnings | -$467.82M | -$458.27M | -$451.07M | -$482.59M | -$475.20M | -2.1% |
| Shareholder equity | $44.20M | $52.93M | $59.02M | $26.49M | $32.83M | -16.5% |
| Working capital | $43.16M | $52.12M | $58.42M | $38.67M | $44.46M | -17.2% |
| Net tangible assets | $44.20M | $52.93M | $59.02M | $26.49M | $32.83M | -16.5% |
| Shares issued | 58.15M | 57.89M | 56.41M | 56.31M | 56.19M | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$9.55M | -$7.20M | $31.52M | -$7.38M | -$1.70M | -32.6% |
| Depreciation & amortisation | — | — | $0 | $0 | — | — |
| Stock-based compensation | $822.00K | $1.11M | $1.01M | $1.05M | $714.00K | -26.2% |
| Change in working capital | $3.15M | $21.73M | -$41.09M | $22.89M | -$16.98M | -85.5% |
| Operating cash flow | -$5.36M | $15.86M | -$8.35M | $17.42M | -$17.69M | -133.8% |
| Free cash flow | -$5.36M | $15.86M | -$8.35M | $17.42M | -$17.69M | -133.8% |
| End cash position | $50.77M | $56.13M | $40.27M | $48.62M | $31.19M | -9.5% |
Options analytics
Put / call volume
0.24
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
0.50
-58.0% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
168
Contracts, this expiry
Put volume
41
Contracts, this expiry
Heaviest call OI
1.50
0 contracts
Heaviest put OI
0.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | — | -0.16 | — |
| Sep 2025 | -0.25 | -0.13 | +48.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.14 | 1 | $0 | -100.0% |
| Next quarter | -0.14 | 1 | $0 | — |
| Current year | -0.58 | 1 | $258.00K | — |
| Next year | -0.11 | 2 | $0 | -100.0% |
Analyst targets & ownership
Mean target$5.00
High target$6.00
Low target$4.00
Implied upside320.17%
Analyst count2
ConsensusNONE
Strong buy / Buy0 / 1
Hold1
Sell / Strong sell0 / 0
Held by insiders22.66%
Held by institutions18.21%
Institutions holding68
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.21
-1.98% from price
SMA 20
1.18
+0.46% from price
SMA 50
1.20
-1.03% from price
SMA 100
1.75
-31.96% from price
SMA 200
2.10
-43.26% from price
EMA 12
1.20
-0.83% from price
EMA 26
1.21
-1.77% from price
EMA 50
1.32
-9.79% from price
RSI (14)
47.4
Neutral
MACD (12,26,9)
-0.01
Hist 0.00
ATR (14)
0.09
7.65% of price
Realised vol 30D
64.3%
Annualised
Bollinger upper
1.31
20, 2σ
Bollinger lower
1.06
20, 2σ
50 / 200 cross
Death
1.20 vs 2.10
Trend bias
Below 200
-43.26%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.45
More volatile than market
Correlation to SPY
0.29
Largely independent
Realised vol 30D
64.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-62.8%
Peak to trough
Max drawdown 5Y
-96.8%
Peak to trough
ATR 14
0.09
7.65% of price
Beta (reported)
1.50
5Y monthly, from filing
Short interest
Shares short
976.49K
Prior 1.45M
Change vs prior
-32.5%
Shorts covering
% of float
2.02%
Normal
% of shares out
1.68%
Against total outstanding
Days to cover
2.7
Liquid
Float
47.10M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 14, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 30, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 20, 24 | Evercore ISI Group | DOWNGRADE | Outperform | In-Line |
| Dec 2, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 18, 24 | TD Cowen | DOWNGRADE | Buy | Hold |
| Nov 15, 24 | Cantor Fitzgerald | MAINTAINED | — | Overweight |
| Nov 4, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 3, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 6, 24 | TD Cowen | UPGRADE | Hold | Buy |
| Aug 6, 24 | Cantor Fitzgerald | MAINTAINED | — | Overweight |
| Aug 6, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 16, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-28
Periodic Financial Reports
10-Q · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-07-14
Corporate Changes & Voting Matters
8-K · 2026-06-25
Offering Registrations
S-8 · 2026-06-23
Corporate Changes & Voting Matters
8-K · 2026-06-22
Periodic Financial Reports
10-Q · 2026-05-13
Annual Report to Shareholders
ARS · 2026-04-27
Headlines
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 5d ago
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 34d ago
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 35d ago
Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript
Motley Fool · 48d ago
Spero Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby · 55d ago
Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ...
GuruFocus.com · 55d ago
Spero Therapeutics Q2 Earnings Call Highlights
MarketBeat · 55d ago
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
GlobeNewswire · 56d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.